Boiron SA (EPA:BOI)

Market Cap	446.21M +9.4%
Revenue (ttm)	501.11M +2.8%
Net Income	32.64M +188.0%
EPS	1.88 +189.2%
Shares Out	17.36M
PE Ratio	13.67
Forward PE	12.50
Dividend	1.20 (4.67%)
Ex-Dividend Date	Jun 3, 2026

Volume	1,187
Average Volume	3,039
Open	25.40
Previous Close	25.70
Day's Range	25.30 - 25.50
52-Week Range	20.85 - 32.25
Beta	0.25
RSI	42.58
Earnings Date	Jul 17, 2026

About Boiron

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices, invitro diagnostics, herbal medicine, food supplements, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 2,736
• Stock Exchange: Euronext Paris
• Ticker Symbol: BOI

Financial Performance

In 2025, Boiron's revenue was 501.11 million, an increase of 2.78% compared to the previous year's 487.56 million. Earnings were 32.64 million, an increase of 187.96%.